Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. by Alsumali, Adnan et al.
Vol.:(0123456789)
PharmacoEconomics (2021) 39:1343–1354 
https://doi.org/10.1007/s40273-021-01091-w
ORIGINAL RESEARCH ARTICLE
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart 
Failure with Reduced Ejection Fraction Following a Worsening Heart 
Failure Event from a US Medicare Perspective
Adnan Alsumali1  · Laurence M Djatche2 · Andrew Briggs3  · Rongzhe Liu4  · Ibrahim Diakite4  · Dipen Patel4  · 
Yufei Wang5 · Dominik Lautsch2 
Accepted: 16 September 2021 / Published online: 8 October 2021 
© Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., Andrew Briggs, Rongzhe Liu, Ibrahim Diakite, Dipen Patel 2021
Abstract
Objective Given the high economic burden of disease among adult patients with chronic heart failure with reduced ejection 
fraction (HFrEF) following a worsening heart failure event in the US, this study aimed to estimate the cost effectiveness of 
vericiguat plus prior standard-of-care therapies (PSoCT) versus PSoCT alone from a US Medicare perspective.
Methods A four-state Markov model (alive prior to heart failure hospitalization, alive during heart failure hospitalization, 
alive post-heart failure hospitalization, and death) was developed to predict clinical and economic outcomes, based on the 
results of the VICTORIA trial, in which patients with chronic HFrEF following a worsening heart failure were randomized 
to placebo or vericiguat, in addition to PSoCT, which consisted of β-blockers, renin-angiotensin-aldosterone inhibitors, 
mineralocorticoid receptor antagonists, and the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan. Risks of heart 
failure hospitalization and cardiovascular mortality were based on multivariable regression models derived from VICTORIA 
data. Utilities were derived from VICTORIA EQ-5D data and the literature. Costs included drug acquisition, heart failure 
hospitalization, routine care, and terminal care. Primary outcomes included heart failure hospitalization, cardiovascular 
mortality, life-years, quality-adjusted life-years (QALYs), and incremental costs per QALY gained over a 30-year lifetime 
horizon, discounted at 3.0% annually.
Results For the VICTORIA overall intent-to-treat population, compared with PSoCT, vericiguat plus PSoCT resulted in 19 
fewer heart failure hospitalizations and 13 fewer cardiovascular deaths per 1000 patients, as well as 0.28 QALY gained per 
patient at an incremental cost of $23,322, leading to $82,448 per QALY gained.
Conclusions Based on the results of VICTORIA, patients treated with vericiguat had lower rates of heart failure hospitaliza-
tion and cardiovascular death. The addition of vericiguat to PSoCT was estimated to increase QALYs and to be cost effective 
at a willingness-to-pay threshold of $100,000 per QALY gained.
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1 Introduction
Heart failure (HF) is an increasingly common condition 
in the US, with a projected prevalence of 8 million adults 
by the year 2030 [1]. Approximately 31–56% of patients 
with HF have reduced ejection fraction (rEF), defined as 
a left ventricular ejection fraction (LVEF) of 40% or less 
[2–8]. Despite the use of prior standard-of-care therapies 
(PSoCT)—which may consist of β-blockers (BBs), renin-
angiotensin-aldosterone (RAAS) inhibitors, mineralocorti-
coid receptor antagonists (MRAs), and angiotensin recep-
tor–neprilysin inhibitors (ARNIs)—patients with HF may 
experience multiple worsening HF events (WHFEs), such 
as unscheduled HF hospitalization (HFH) or initiation of 
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Key Points for Decision Makers 
Given the high economic burden in patients with heart 
failure with reduced ejection fraction (HFrEF) who have 
recently experienced worsening HF event(s) in the US, 
this study intends to assess whether vericiguat is cost 
effective as an add-on therapy to prior standard-of-care 
therapies (PSoCT) versus PSoCT alone in the VICTO-
RIA trial population from a US Medicare perspective.
Vericiguat plus PSoCT compared with PSoCT alone 
resulted in an incremental cost of $82,448 per QALY 
gained.
Vericiguat plus PSoCT was estimated to result in longer 
life expectancy and to be cost effective at a willingness-
to-pay threshold of $100,000 per QALY gained in the 
overall VICTORIA intent-to-treat population.
VICTORIA was a randomized, placebo-controlled, 
double-blind, event-driven, multicenter, phase III clinical 
outcomes trial that tested the efficacy and safety of veri-
ciguat versus placebo on top of PSoCT [9]. VICTORIA had 
a specific population of patients living with HFrEF who had 
a recent HFH of <6 months or outpatient intravenous diu-
retic therapy for <3 months. Vericiguat reduced the primary 
composite outcome of CV death or HFH compared with 
placebo (897 of 2526 patients in the vericiguat group vs. 972 
of 2524 patients in the placebo group; hazard ratio 0.90, 95% 
confidence interval 0.82–0.98; p = 0.02).
Given the economic burden of HFrEF following a WHFE, 
it is important for US payers and other healthcare decision 
makers to understand the clinical and economic benefits of 
adding vericiguat to the formulary for treatment in this popu-
lation. Thus, the objective of this study was to estimate the 




An HF disease simulation model was developed in Microsoft 
Excel 365 (Microsoft Corporation, Redmond, WA, USA) 
to assess the cost effectiveness of vericiguat plus PSoCT 
versus PSoCT alone for the treatment of adult patients with 
chronic HFrEF (LVEF <45%) following a WHFE, in line 
with the definitions of patient population and PSoCT in the 
VICTORIA trial [9]. The analysis was conducted from a US 
Medicare perspective over a lifetime horizon, which was 
assumed to be 30 years, based on the baseline mean age of 
67.3 years of the VICTORIA intent-to-treat (ITT) population 
[9]. This assumption was also supported by the simulation 
result that more than 99.9% of patients would experience 
mortality within 30 years since model baseline. Cost and 
clinical outcomes were discounted at 3.0% annually, in line 
with the Institute for Clinical and Economic Review’s Refer-
ence Case for Economic Evaluations [21].
2.2  Model Structure
A multistate Markov model with four mutually exclusive 
states (i.e., alive prior to the first HFH since baseline, alive 
during the first HFH, alive post the first HFH, and dead) 
was developed to predict the occurrence of HFH and CV 
death and to estimate the associated costs (Fig. 1). At model 
baseline, all patients started in the ‘alive prior to the first 
HFH’ health state and moved through the model’s health 
states according to a set of transition probabilities on a cycle 
basis (see more details of health state transition in the Sup-
plementary Methods section of the electronic supplementary 
intravenous diuretic therapy [9, 10]. Approximately 30% of 
patients with chronic HF with rEF (HFrEF) experience at 
least one WHFE within the first year of diagnosis [11, 12], 
and each event places patients at increased risk of additional 
events [13, 14].
WHFEs negatively impact prognosis and are associated 
with considerable clinical and economic burden in the US. 
The 2-year mortality rate in patients with HFrEF who expe-
rienced a WHFE was estimated at 23% [14, 15]. Patients 
with HFrEF who experience a WHFE are at high risk for 
recurrent HFH [14], and after each subsequent HFH, the 
mortality rates significantly increase [16, 17]. Inpatient hos-
pitalization costs were the primary driver of total costs in HF 
[11, 18–20], and direct medical costs of HF in the US were 
projected to increase from $20.9 billion in 2012 to $53.1 
billion in 2030 [20]. Medical resource use and costs are also 
significantly higher for patients with chronic HFrEF follow-
ing a WHFE compared with patients with stable chronic 
HFrEF [11, 12], therefore further treatment options are 
needed in this population.
Vericiguat, a soluble guanylate cyclase (sGC) stimula-
tor, was approved by the US FDA in January 2021 and is 
indicated to reduce the risk of cardiovascular (CV) death 
and HFH following a hospitalization for HF or need for 
outpatient intravenous diuretics in adults with sympto-
matic chronic HF and ejection fraction <45%. The approval 
was based on the results of the pivotal VICTORIA trial 
(NCT02861534).
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material [ESM]). A cycle length of 1 month was adopted 
because those in the VICTORIA trial population were con-
sidered to be in an advanced disease stage and the duration 
of the first HFH is explicitly restricted to be, at most, 30 
days. Furthermore, this cycle length provides the appropri-
ate level of detail in the model. Half-cycle correction was 
applied in the model. The proportion of patients occupy-
ing the four different health states in each model cycle was 
applied to estimate the accrued costs and clinical outcomes 
of the patient cohort over time.
2.3  Model Inputs
2.3.1  Heart Failure Hospitalization (HFH), Cardiovascular 
(CV) Death, and Non‑CV Death
The clinical outcomes of HFH and CV death in the ITT 
population of the VICTORIA trial were used to inform the 
base-case analysis. Multivariable regression models fitted 
to VICTORIA trial data were applied to predict HFH and 
CV death over time, with treatment arm (i.e., vericiguat plus 
PSoCT versus PSoCT alone) and baseline patient charac-
teristics included as covariates (Table 1; Supplementary 
Table 1 and Supplementary Table 2 in the ESM). Four 
regression models were applied to inform four health state 
transitions: (1) first HFH after inclusion into VICTORIA 
since trial baseline; (2) risk of CV death among patients who 
had not experienced the first HFH since trial baseline; (3) 
risk of CV death among patients during the first HFH; and 
(4) risk of CV death among patients who had experienced 
the first HFH. These transitions were derived from (1) a 
parametric regression model with an exponential distribu-
tion; (2) a parametric regression model with a generalized 
gamma distribution; (3) a logistic regression model; and (4) 
a parametric regression model with a Gompertz distribu-
tion, respectively (Supplementary Fig. 1 in the ESM) in the 
Fig. 1  Markov model structure. Note: Transitions to death were based 
on two components: CV death (based on risk equations from VICTO-
RIA) and non-CV death (based on a US life table adjusted by remov-
ing CV mortality). Details of each health state transition are provided 
in the Supplementary Methods section in the electronic supplemen-
tary material. HFH heart failure hospitalization, CV cardiovascular
Table 1.  Model input values for baseline patient characteristics of the 
VICTORIA ITT population
Data are expressed as n (%) unless otherwise specified
BMI body mass index, bpm beats per minute, COPD chronic obstruc-
tive pulmonary disease, eGFR estimated glomerular filtration rate, 
HF heart failure, HFH heart failure hospitalization, ITT intent-to-
treat, LVEF left ventricular ejection fraction, mEq/L milliequivalents 
per liter, NT-proBNP N-terminal pro-B-type natriuretic peptide, 
NYHA New York Heart Association, WHFE worsening heart failure 
event
a These were subjects with full information on the baseline patient 
characteristics selected for the multivariable parametric models for 
cardiovascular mortality and heart failure hospitalization. Subjects 






Age, years (mean) 67.28
Geographic region or race/ethnicity
 Eastern European 1575 (33.3)
 Western European 781 (16.5)
 Asia Pacific 1152 (24.4)
 Latin and South America 704 (14.9)
 North America, African American 113 (2.4)
 North America, Non-African American 406 (8.6)
Laboratory results
NT-proBNP, pg/mL (mean) 4740.79
eGFR, mL/min/1.73m2 (mean) 61.50




Diabetes mellitus 2217 (46.9)
Ischemic etiology 3035 (64.2)
WHFE
 HFH within 3–6 months before randomization 806 (17.0)
 HFH within 3 months before randomization 3164 (66.9)
 Intravenous diuretic for HF (without HFH) 
within 3 months before randomization
761 (16.1)
Other




Heart rate, bpm (mean) 73.13
BMI, kg/m2 (mean) 27.74
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base-case analysis. The selection of parametric distributions 
was based on clinical assumption as assessed via clinical 
experts’ opinions. Specifically, two clinical assumptions 
were made: (1) the baseline risks of CV mortality and HFH 
would increase over time (age), in line with prior cost-
effectiveness models for HFrEF [22–24]; and (2) the life 
expectancy of the modeled population was expected to be 
relatively short, given that the VICTORIA trial population 
represented patients who had experienced a WHFE with a 
poor prognosis.
For transition to the first HFH after inclusion into VIC-
TORIA, the exponential distribution was applied, as all 
other distributions were ruled out due to a lack of clinical 
plausibility. More specifically, all other distributions were 
associated with decreasing hazards in the long term that 
were either monotonically decreasing or first increasing for 
a short period of time (<3 months) and then decreasing for 
the rest of the lifetime horizon. Therefore, the exponential 
distribution was considered the most clinically plausible one 
among all the distributions and was therefore applied in the 
base-case analysis. The risk of CV death among patients 
during the first HFH was modeled by using logistic regres-
sion because the first HFH was restricted to a very short 
time (at most 30.4375 days). For the risk of CV death among 
patients who were not in HFH, similar to the risk of HFH, 
the distributions with increasing hazards were applied in the 
base-case and scenario analyses. More details of the regres-
sion models are provided in the Supplementary Methods 
section of the ESM, including, but not limited to, the coef-
ficient estimates and the functions used to derive the health 
state transition probabilities by parametric distribution.
Non-CV mortality was based on US life tables adjusted 
by removing CV mortality [25, 26], in line with previous 
cost-effectiveness analyses in HFrEF [23, 24, 27, 28]. The 
model did not include adverse events, given that there was 
no significant difference in safety profiles between the veri-
ciguat plus PSoCT and placebo plus PSoCT arms in VIC-
TORIA [9].
2.3.2  Utilities
To estimate the quality-adjusted life-years (QALYs) for 
patients over time, we multiplied the time spent in each 
health state by the utility associated with each health state. A 
utility of 0 usually represents death and a utility of 1 repre-
sents perfect health. The utility for health states not in HFH 
(i.e., alive pre- or post-HFH) was derived from the baseline 
EQ-5D-5L in the VICTORIA ITT population using the US 
value set (Table 2). As patients who were hospitalized due 
to HF were expected to have poorer health-related quality of 
life (HRQoL) than patients not in HFH, a utility decrement 
was applied on top of the utility without HFH to estimate the 
utility with HFH. Due to a lack of EQ-5D measurement dur-
ing HFH in the VICTORIA trial to capture the acute effect 
of HFH on quality of life, the utility decrement of HFH was 
based on external literature [22] (Table 2).
2.3.3  Healthcare Resource Use and Cost Inputs
The model included costs for drug acquisition, HFH, routine 
care, and terminal care. Cost inputs were inflated to 2020 US 
dollars using the medical care component of the Consumer 
Price Index [29].
Daily drug acquisition costs for vericiguat and each indi-
vidual PSoCT (including angiotensin-converting enzyme 
inhibitors [ACEi] or angiotensin receptor blockers [ARBs], 
BBs, sacubitril/valsartan, and MRAs) (Table 2) were calcu-
lated as the product of cost per tablet and number of tablets 
per day for each drug (Supplementary Table 3 in the ESM). 
Target doses of PSoCT and vericiguat were obtained from 
the products’ prescribing information [30–34]. Drug whole-
sale acquisition costs (WACs) and package information for 
PSoCT drugs and vericiguat were obtained from the RED 
BOOK [35]. It was also assumed that patients would initiate 
treatment upon model entry and continue until death, in line 
with drug prescribing information where no discontinuation 
rule was specified [30–34]. A one-time cost per HFH [29, 
36] was applied upon HFH admission; a monthly routine 
care cost [11, 29, 36] was applied for as long as a patient 
remained alive; and a one-time terminal care cost [29, 37] 
was applied upon death, regardless of the cause of death 
(Table 2).
2.4  Outcomes
Clinical and economic outcomes were compared between 
the vericiguat plus PSoCT arm and the PSoCT-alone arm, 
including the average number of HFHs and CV deaths per 
1000 patients, as well as average life-years, QALYs, and 
costs per patient. Per patient incremental cost per QALY 
gained was estimated, defined as the difference in total costs 
divided by the difference in total QALYs between the two 
treatment arms. A willingness-to-pay (WTP) amount of 
$100,000 per QALY gained was used to assess a strategy’s 
cost effectiveness, an incremental cost per QALY below 
which is considered cost effective [21].
2.5  Sensitivity Analyses
Scenario analyses were conducted for structural or input 
assumptions, including time horizon, annual discounting 
rates for future costs and clinical outcomes, alternative 
distributions of parametric regression models that were 
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Table 2.  Model input values for PSoCT utilizations, costs, and utilities
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, HFH heart failure hospitalization, MRA mineralocorticoid 
receptor antagonist, PSoCT prior standard-of-care therapies, WHFE worsening heart failure events
a The utilization rates in the total VICTORIA intent-to-treat population were applied to both treatment arms
b Detailed drug wholesale acquisition costs and drug dosage used to estimate daily drug costs are shown in Table 2 in the electronic supplemen-
tary material
c The daily cost of vericiguat applied in the cost-effectiveness analysis (i.e., $14.57) was estimated as the daily wholesale acquisition cost 
($19.43), with an extra 25% discount (the discount for vericiguat was assumed to be the same as that for sacubitril/valsartan below)
d The daily cost of sacubitril/valsartan applied in the cost-effectiveness analysis (i.e., $14.57) was estimated as the daily wholesale acquisition 
cost ($19.43), with an extra 25% discount (an assumption to provide an approximation of the net price based on unpublished historical pricing 
data of sacubitril/valsartan)
e The HFH cost of $10,419 was estimated by inflating the HFH cost per admission of $9733 (2018 US dollars) among Medicare fee-for-service 
enrollees with WHFE from Mentz et al. [36], identified from a targeted literature review. Scenario analyses (see Table 4) were conducted using 
costs specific for Medicare Advantage and commercial health plan enrollees. Our input values in the base-case and scenario analyses were 
shown to be plausible as per Urbich et al. [42], a systematic literature review for medical costs associated with HF in the US, in which a range of 
$7319–$30,475 (2019 US dollars; payer type unspecified) was reported for HFH cost
f The monthly routine care cost of $287 prior to HFH was estimated by inflating the monthly HF-related outpatient cost of $268 (2018 US dol-
lars) in Medicare fee-service enrollees with WHFE from Mentz et al. [36]. There was a lack of reporting of monthly HF-related routine care cost 
in Urbich et al. [42] for potential external validation. Scenario analyses (see Table 4) were conducted using costs specific for Medicare Advan-
tage and commercial health plan enrollees obtained from more recent literature after publication of the systematic review by Urbich et al. [42]
g The monthly cost of routine care in or post HFH was estimated by applying a ratio of 2.17 to the monthly cost of $287 prior to HFH. The ratio 
of 2.17 was derived from Butler et al. [11], which compared the monthly HF-related routine care cost between patients with stable HFrEF ($132) 
and patients with a recent WHFE ($132) in the commercially insured population
h The terminal care cost of $9148 per mortality event was estimated by inflating the average HF-related medical cost of $7495 (2013 US dol-
lars) among Medicare Advantage enrollees in their last month before death from the study by Obi et al [37]. This reference was identified from a 
targeted literature review. There was a lack of reporting of terminal care cost from Urbich et al. [42] for potential external validation. A scenario 
analysis (see Table 4) was conducted using commercial payer-specific costs
i The utility for patients alive and not alive in HFH (0.8) was derived from baseline EQ-5D-5L data in the VICTORIA intent-to-treat population 
using the US value set. The model assumes no treatment-specific benefit related to EQ-5D. When patients move to the ‘alive post the first HFH’ 
health state after HFH, we assumed the utility would increase back to 0.8
j Patients who were hospitalized due to HF were expected to have poorer health-related quality of life than patients not in HFH; therefore, a util-
ity decrement was applied on top of the utility without HFH to estimate the utility with HFH. Due to a paucity of EQ-5D data from VICTORIA 
that coincided with HFH, a disutility of 0.077 was estimated based on Sandhu et al. [22] (identified from a targeted literature review of prior US 
cost-effectiveness models, as shown in Supplementary Table 4), in which a 9.7% decrease was assumed for patients in HFH. The disutility value 
(0.077) applied in our analysis was shown to be plausible as per Di Tanna et al. [41], a systematic literature review for health-related quality of 
life in patients with HF, in which a range of 0.001 to approximately 0.1 was reported for utility decrements due to hospitalization
Parameter Value Source
Proportion of patients treated with individual PSoCT component [n/N (%)]a
ACEi or ARB 3700/5040 (73.4) VICTORIA [9]
β-blockers 4691/5040 (93.1) VICTORIA [9]
Sacubitril/valsartan 731/5040 (14.5) VICTORIA [9]
MRA 3545/5040 (70.3) VICTORIA [9]
Costs
 Drug costs per dayb
  Vericiguat 14.57 RED BOOK [35], prescribing information [34]c
  ACEi or ARB 0.03 RED BOOK [35], prescribing information [30]
  β-blockers 0.05 RED BOOK [35], prescribing information [31]
  Sacubitril/valsartan 14.57 RED BOOK [35], prescribing information [32]d
  MRA 0.11 RED BOOK [35], prescribing information [33]
 Medical costs
  HFH cost per event 10,419 Mentz et al. [29, 36]e
  Routine care cost prior to HFH, per month 287 Mentz et al. [29, 36]f
  Routine care cost during or post HFH, per month 624 Mentz et al. [36]; Butler et al. [11, 29]g
  Terminal care cost, per mortality event 9,148 Obi et al. [29, 37]h
Utilities
Alive prior to HFH 0.800 VICTORIAi
Alive during HFH 0.723 Sandhu et al. [22]j
Alive post HFH 0.800 Assumed to be the same as (alive prior to HFH)
1348 A. Alsumali et al.
potentially clinically plausible, potential drug cost discount 
for both vericiguat and sacubitril/valsartan, and medical cost 
inputs.
Uncertainty of quantitative parameters was assessed via 
univariate (or one-way) and probabilistic sensitivity analyses 
(PSA). The uncertainty around the central estimate was set 
according to variance information provided in the original 
source. Where variance information was not available (for 
three parameters: HFH cost, routine care cost, and terminal 
care cost), the standard error was typically assumed to be 
20% of the mean. For probabilities (including the proportion 
of patients treated with each individual PSoCT component) 
and utility of being alive but not in HFH, a beta distribution 
was used. For disutility of HFH, costs, and resource use 
estimates, a gamma distribution was fitted. For regression 
models, multivariate normality on the scale of estimation 
was assumed using the Cholesky decomposition approach 
employed to capture the correlation structure in the vari-
ance–covariance matrix [38]. Detailed standard error and 
distribution information for the model parameters varied in 
univariate sensitivity analyses and PSA is provided in Sup-
plementary Table 6 in the ESM.
The results of the univariate sensitivity analyses, in which 
each parameter was varied within the 95% confidence inter-
val, were presented using tornado plots to show the top 
parameters that created the widest range in model results. 
The PSA sampled from the distribution of each model 
parameter 1000 times. The results of each probabilistic 
model run were presented via the cost-effectiveness accept-
ability curve.
3  Results
3.1  Base Case
In the base case over a 30-year lifetime horizon, our model 
predicted 681 HFHs and 427 CV deaths per 1000 patients 
treated with vericiguat plus PSoCT, compared with 700 
HFHs and 440 CV deaths per 1000 patients treated with 
PSoCT alone, resulting in 19 fewer HFHs and 13 fewer CV 
deaths with vericiguat plus PSoCT. A discounted average 
of 4.18 years of survival and 3.34 QALYs was estimated 
per patient treated with vericiguat plus PSoCT compared 
with 3.82 years of survival and 3.05 QALYs per patient 
treated with PSoCT alone, resulting in an incremental gain 
of 0.35 years of survival and 0.28 QALYs with vericiguat 
plus PSoCT. Treatment with PSoCT was associated with 
lifetime costs of $60,228 per patient. The addition of veri-
ciguat increased the lifetime costs by $23,322, including 
an additional $22,526 in drug acquisition costs and $1093 
in routine care costs, but with savings of $202 and $95 in 
HFH and terminal care costs, respectively. At the commonly 
accepted WTP threshold of $100,000 per QALY gained in 
the US [21], adding vericiguat to PSoCT is considered cost 
effective ($82,448 per QALY gained) [Table 3].
3.2  Scenario Analyses
The costs per QALY gained from treatment with vericiguat 
plus PSoCT were estimated to be $90,494 and $82,557 
over 10- and 20-year time horizons, respectively. Use of 
alternative parametric distributions for risks of CV death 
post-HFH was associated with costs of $76,049–$89,004 
per QALY gained. Using alternative Medicare medical 
costs and commercial payer-specific medical costs led to 
$80,507 and $80,983 per QALY gained, respectively. In a 
more conservative scenario where terminal care cost was 
set as zero, the cost per QALY gained was estimated to be 
$82,785. Decreasing the WAC of both vericiguat and sacu-
bitril/valsartan by 20, 30, and 35% was associated with 
costs of $85,329, $74,720, and $69,415 per QALY gained, 
respectively, in comparison with $82,448 in the base case, 
where WAC was decreased by 25% (Table 4, Supplementary 
Table 7).
3.3  Univariate Sensitivity Analyses
The results of the univariate sensitivity analyses showed that 
the costs per QALY gained were most sensitive to the coef-
ficients for (1) rate of the Gompertz distribution related to 
the risk of CV death post HFH; (2) baseline predose sodium 
level related to the risk of CV death post HFH; and (3) inter-
action between the treatment and baseline N-terminal pro-
B-type natriuretic peptide (NT-proBNP) level related to the 
risk of first HFH after inclusion into VICTORIA (Fig. 2).
3.4  Probabilistic Sensitivity Analyses
At a WTP threshold of $100,000 per QALY gained, the 
probability of vericiguat plus PSoCT being cost effective 
compared with PSoCT alone was estimated to be 70%; how-
ever, at a WTP threshold of $150,000, the probability of 
vericiguat plus PSoCT being cost effective increased to 88% 
(Supplementary Figs. 2 and 3 in the ESM).
3.5  Validation
Both internal and external validations were conducted. 
For external validation, as discussed earlier, the selec-
tion of parametric regression models was based on clini-
cal experts’ opinions regarding clinical plausibility. In 
particular, we consulted with cardiologists and clinical 
experts in the field of HF through virtual meetings, during 
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which we presented all the fitted parametric regression 
models (i.e., exponential, Weibull, Gompertz, log-normal, 
log-logistic, gamma, and generalized gamma) for each 
health state transition to ensure appropriate hazard pat-
terns over time. The projected outcomes were plausible 
from a clinical standpoint. A further external validation 
with real-world data was planned but could not yet be 
carried out due to a paucity of data on survival outcomes 
in the VICTORIA patient population. Prior studies in 
HFrEF—both clinical and observational—included rela-
tively heathier HFrEF populations and therefore cannot 
be used for the validation of our model results. In addi-
tion, the predicted life expectancy was validated against 
previous US cost-effectiveness analyses for patients with 
HFrEF [22, 28, 39, 40].
For internal validation, a comparison of the predicted 
model results and the observed trial results per the study by 
Armstrong et al. [9] is provided (Supplementary Table 5) 
and shows an alignment in the results, especially for the 
incremental outcomes between the two treatment arms at 
12 months. In addition to clinical inputs, the medical cost 
and HRQoL inputs applied in the base-case and scenario 
analyses were validated through a review of two recently 
published systematic literature reviews for costs and utilities 
in patients with HF [41, 42], which showed that the input 
values in our model were plausible. Lastly, a quality check of 
the model was conducted using the TECHnical VERifcation 
(TECH-VER) checklist [43].
4  Discussion
Following FDA approval based on the results of the VICTO-
RIA trial, vericiguat represents an innovative treatment that 
fills the medical needs for a distinct HFrEF population with 
recent worsening HF and higher natriuretic peptide levels, 
i.e., a sicker population associated with a higher economic 
burden compared with the HFrEF populations in other recent 
trials (e.g., DAPA-HF and PARADIGM-HF). Our analysis 
suggests that vericiguat plus PSoCT could be a cost-effective 
treatment option for patients with chronic HFrEF following 
a WHFE, compared with PSoCT alone. Using VICTORIA 
trial data in the model, we estimated, over a 30-year lifetime 
horizon, vericiguat plus PSoCT would result in 19 fewer 
HFHs and 13 fewer CV deaths per 1000 patients, and an 
additional 0.28 QALYs gained per patient at an incremental 
cost of $82,448 per QALY gained.
Sensitivity analyses showed that the results of the base-
case analysis were robust. In the scenario analyses in which 
time horizon, annual discounting, drug acquisition costs of 
both vericiguat and sacubitril/valsartan, parametric distri-
bution for risk of CV death, and medical cost inputs were 
varied, vericiguat plus PSoCT was consistently associated 
with fewer HFHs and CV deaths compared with PSoCT 
alone, with incremental costs per QALY gained lower than 
$100,000. The PSA results showed that the probability of 
vericiguat plus PSoCT being cost effective was 70% at a 
WTP threshold of $100,000 per QALY gained. Univariate 
sensitivity analyses showed that the costs per QALY gained 
Table 3.  Base-case analysis 
deterministic  resultsa
CV cardiovascular, HFH heart failure hospitalization, LYs life-years, PSoCT prior standard-of-care thera-
pies, QALYs quality-adjusted life-years




Total LYs per patient 4.18 3.82 0.35
Alive, prior to HFH 2.93 2.54 0.38
Alive, during or post HFH 1.25 1.28 −0.03
Total QALYs per patient 3.34 3.05 0.28
Alive, prior to HFH 2.34 2.04 0.31
Alive, during or post HFH 0.99 1.02 −0.02
Number of events per 1000 patients
HFH 681 700 −19
CV mortality 427 440 −13
Total costs per patient $60,228 $36,907 $23,322
Drug acquisition $25,686 $3,160 $22,526
HFH $7093 $7295 −$202
Routine care $19,430 $18,337 $1093
Terminal care $8020 $8,115 −$95
Incremental cost per QALY gained per patient $82,448
Incremental cost per LY gained per patient $65,988
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were most sensitive to the variation in the coefficients of risk 
equations, e.g., the coefficient of baseline predose sodium 
level related to the risk of CV death post HFH, and the coef-
ficient of interaction between vericiguat treatment effect and 
baseline NT-proBNP level related to the risk of first HFH. 
These univariate sensitivity analyses are important given the 
consistency with the subgroup analysis of VICTORIA. Veri-
ciguat was associated with a more favorable treatment effect 
in patients with a lower baseline NT-proBNP compared with 
patients who had a higher baseline NT-proBNP level [9].
The lifetime estimates of life expectancy, QALYs, and 
costs for PSoCT alone from our analysis were slightly lower 
than those reported in previous US cost-effectiveness analy-
ses for patients with HFrEF [22, 28, 39, 40] (Supplementary 
Table 3 in the ESM). For example, our estimate of dis-
counted life expectancy of 3.82 years for PSoCT was slightly 
lower than previous estimates (6.04–8.40 years over a life-
time horizon) [22, 28, 39, 44], while our estimate of 3.05 
discounted QALYs for PSoCT was also lower than that in 
the literature (4.53–6.02 QALYs over a lifetime horizon) [22, 
28, 39, 40, 44]. Such differences were likely due to the fact 
that the VICTORIA population had recently experienced a 
WHFE [9] and therefore had worse prognoses and clinical 
outcomes. Furthermore, the event rate in the control arm of 
VICTORIA [9] was much higher than that of the other tri-
als in HFrEF, such as PARADIGM-HF [45] and DAPA-HF 
[46]. In addition, unlike the previous analyses that examined 
ACEi specifically [22, 28, 39, 40], the PSoCT-alone arm of 
Table 4.  Scenario analysis results
CV cardiovascular, HFH heart failure hospitalization, LYs life-years, PSoCT prior standard-of-care therapies, QALYs quality-adjusted life-years, 
WHFE worsening heart failure events
a The daily cost of both sacubitril/valsartan and vericiguat applied in the cost-effectiveness analysis (i.e., $14.57) was estimated as the daily 
wholesale acquisition cost for sacubitril/valsartan (i.e., $19.43), with an extra 25% discount (assumption)
b In the base case, the HFH and routine care costs were based on Medicare fee-for-service costs, whereas the terminal care cost was based on 
Medicare Advantage costs (see Table 2 for more details of base-case input estimates and references)
c The references and estimation of the alternative Medicare costs applied in the scenario analysis were exactly the same as those adopted for the 
base-case analysis. The exception is that in the base-case analysis, the HFH and routine care costs were based on Medicare fee-for-service costs, 
whereas in the scenario analysis, the HFH and routine care costs were based on Medicare Advantage costs
d The HFH cost of $23,605 was estimated by inflating the HFH cost per admission of $22,050 (2018 US dollars) among Medicare Advantage 
enrollees with WHFE from Butler et al. [11]. The monthly routine care cost of $307 prior to HFH was estimated by inflating the monthly HF-
related outpatient cost of $287 (2018 US dollars) in Medicare Advantage enrollees with WHFE from Butler et al. [11]. Same as the base-case 
analysis, the monthly cost of routine care in or post HFH was estimated by applying a ratio of 2.17 (per Butler et al. [11]) to the monthly cost 
prior to HFH. The terminal care cost of $31,779 per mortality event was estimated by inflating the average HF-related medical cost of $26,037 
(2013 US dollars) among commercially insured enrollees in their last month before death from Obi et al. [37]






Cost per QALY 
gained per patient
Base case $23,322 0.28 $82,448
Discounting rate per year for 









Parametric distribution for 
risk of CV death post HFH
Gompertz Weibull $28,546 0.36 $78,946
Gamma $28,745 0.30 $95,164
Daily drug acquisition cost 
of both vericiguat and 
sacubitril/valsartan
$19.43 with 25% discount 
($14.57)a
$19.43 with 35% discount 
($12.63)
$20,321 0.28 $71,839
$19.43 with 30% discount 
($13.60)
$21,821 0.28 $77,143
$19.43 with 20% discount 
($15.54)
$24,822 0.28 $87,753
HFH cost per HFH event; 
routine care cost per month 
prior to HFH; routine care 
cost per month post HFH; 
terminal care cost per 
mortality event
Medicare  perspectiveb: 








 perspectived: $23,605; 
$307; $668; $31,779
$22,908 0.28 $80,983
$0 for the terminal care cost $23,417 0.28 $82,785
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our analyses included a mix of ACEi, ARBs, BBs, sacubi-
tril/valsartan, and MRAs. In addition, consistent with the 
comparisons above of life-years and QALYs, our estimate 
of the discounted cost of $21,685 for PSoCT was lower than 
that in most of the prior models ($83,303–$145,371 over a 
lifetime horizon) [22, 39, 40] One exception is one model 
that reported a cost of $21,758 for the standard-of-care arm 
[28], likely driven by the fact that the longer patients lived, 
the more costs would be incurred over time, and vice versa. 
Another reason might be that our study adopted a Medicare 
perspective in which lower medical cost inputs were applied, 
whereas the prior studies adopted a general US payer per-
spective without being restricted to public or private payers.
Our analysis has several strengths. First, in contrast to 
many previous cost-effectiveness analyses in HFrEF that 
adopted a Markov model based on either the occurrence of 
mortality (with two health states: alive, death) [23, 24, 40], 
the progression per New York Heart Association (NYHA) 
class [28, 47] and/or treatment intolerance (Supplementary 
Table 5 in the ESM) [22, 47], this analysis adopted a four-
state Markov model based on the occurrence of HFH and CV 
death (alive prior to the first HFH, alive during the first HFH, 
alive post the first HFH, and death), which better reflected 
the clinical pathway of patients with chronic HFrEF, espe-
cially for patients who had experienced a WHFE (e.g., the 
VICTORIA trial population) who were at higher risk of CV 
mortality pre and post the next WHFE. More specifically, 
as shown in Supplementary Fig. 1 in the ESM, patients 
who had not experienced HFH since the model entry were 
associated with a lower risk of CV death (indicated by the 
slower drop of survival curves) compared with the patients 
in or post-HFH (with a faster drop of survival curves). By 
modeling separately patients who had or had not experi-
enced HFH since the model baseline, this model allows for 
the differentiation of these patients regarding CV mortal-
ity. This is particularly important for the VICTORIA trial 
population, who were relatively sicker (driven by the recent 
WHFE experience right before the trial randomization) and 
therefore at higher risk of CV death post any WHFE com-
pared with the HFrEF population included in other trials 
(e.g., PARADIGM-HF, SHIFT, or DAPA-HF) and modeled 
for cost effectiveness [22, 28, 39, 40, 44]. In contrast, the 
previously commonly adopted Markov model structure used 
to model based on the PARADIGM-HF, SHIFT, or DAPA-
HF trial populations (relying on the occurrence of mortality, 
NYHA class progression, transplantation, or treatment intol-
erance) [22–24, 28, 40, 44, 47] would not be able to capture 
the differences in baseline risk and treatment effect pre ver-
sus post the first HFH, and was therefore less appropriate 
for this model specific to the VICTORIA trial population.
Second, the analysis relied on clinical experts’ opinions 
as to which parametric distributions (e.g., Gompertz) were 
associated with clinically plausible outcomes of HFH and 
CV death over time. This led to more clinically relevant 
choices of the analysis results. Third, by including baseline 
patient characteristics that were key prognostic factors as 
covariates in the parametric models for HFH and CV death, 
Fig. 2  Univariate sensitivity analyses for parameter impact on incre-
mental costs per QALY gained. Notes: The top 10 most impact-
ful parameters included in univariate sensitivity analyses are shown 
above. For the list of parameters included in the analyses and the 
associated deterministic point estimates, standard errors, and dis-
tributions, please refer to Supplementary Table  6 in the electronic 
supplementary material. In these sensitivity analyses, negative costs 
per QALY gained indicate that the vericiguat plus PSoCT arm is 
dominated by PSoCT alone. CV cardiovascular, exp. Exponential, 
Gen. gamma generalized gamma, HFH heart failure hospitalization, 
NT-proBNP N-terminal pro-B-type natriuretic peptide, PSoCT prior 
standard-of-care therapies, QALY quality-adjusted life-year
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this analysis captured the effect of these factors on long-term 
outcomes, which may be more clinically meaningful.
Despite the strengths and robustness of the base-case 
results, as demonstrated by sensitivity analyses above, 
some limitations should be considered when interpreting 
the results. First, this analysis relied on VICTORIA trial 
data with a median follow-up of 10.8 months [9] to pre-
dict the risks of HFH and CV death over a lifetime horizon, 
which could lead to uncertainty of long-term extrapolation. 
In particular, at the end of the trial follow-up, 27.4–29.6% of 
VICTORIA patients had the first HFH since trial baseline, 
while CV death occurred in 16.4–17.5% of patients [9]. Still, 
this is a common limitation of most disease simulation mod-
els, and the uncertainty of extrapolation has been examined 
through both clinical validation by clinicians and statistical 
assessment via the PSA.
Second, similar to the first limitation above, due to the 
limited number of events observed within the VICTORIA 
trial period, this analysis did not capture the subsequent 
HFH, despite the expectation that patients with HF would 
experience multiple WHFEs (i.e., HFH or outpatient initia-
tion of intravenous diuretic therapy) [9, 10] and that each 
WHFE could increase the risk of additional WHFEs [13, 
14].
Third, no real-world data are currently available on veri-
ciguat adherence to understand the potentially waning dif-
ferences in treatment effect for those who discontinued over 
time. Therefore, adherence was not considered in the analy-
sis. When real-world data become available, a further exter-
nal validation for the current model is advisable on survival 
and HFH outcomes for the VICTORIA patient population.
Fourth, this study did not model any numeric differences 
in adverse events, given that the VICTORIA trial did not 
show statistically significant differences in the safety profiles 
of the vericiguat plus PSoCT and placebo plus PSoCT arms 
(32.8% of patients in the vericiguat arm experienced at least 
one serious adverse event vs. 34.8% in the placebo arm) [9].
Fifth, the results of this model based on VICTORIA 
trial data may not always be generalizable to the real-world 
HFrEF population in the case of evolving treatment para-
digms. For example, emerging treatments such as sodium-
glucose cotransporter-2 (SGLT2) inhibitors were not gener-
ally used in VICTORIA because SGLT2 inhibitors were not 
part of the guideline-directed medical therapies at the time 
of the trial. However, a small fraction of patients did use 
SGLT2 inhibitors in VICTORIA, with a balance between 
both groups. Despite the recent FDA approval of the SGLT2 
inhibitors dapagliflozin and empagliflozin, it might take time 
for SGLT2 inhibitors to be widely used in real-world prac-
tice. There are a lack of clinical or real-world data regard-
ing whether vericiguat would be prescribed on top of newer 
treatments or in lieu of them.
Furthermore, while we adopted a US Medicare perspec-
tive to be aligned with the baseline mean age of the VIC-
TORIA population and applied Medicare-specific medical 
cost inputs, the costs could vary by health plan and site of 
care. Therefore, we conducted scenario analyses to examine 
the impact of using alternative Medicare costs and com-
mercial payer-specific costs separately, which showed that 
the medical costs had limited impact on the model results. 
In addition, we expected that the cost of hospital-based ter-
minal care could differ from the cost in the community set-
ting. Therefore, we also conducted a conservative scenario 
analysis by zeroing out terminal care cost from the model, 
which had only a limited effect on the model results. In addi-
tion, for the drug costs, we relied on WAC and assumed 
a discount of 25% to approximate the net price for both 
vericiguat and sacubitril/valsartan, as the net price of the 
recently launched vericiguat was not available at the time of 
this analysis. To mitigate this limitation, scenario analyses 
were conducted to examine the impact of varying the drug 
discount on the model results.
Finally, non-drug costs can be determined based on differ-
ent sources, as recently consolidated [42]. We chose to base 
our model on the most recently published HCRU cost data 
in the US that further allow to distinguish Medicare patients 
who had, versus those who did not have, a recent worsening 
HF event based on the unique population described [11, 36].
5  Conclusions
VICTORIA enrolled a population with recent worsening HF 
and higher natriuretic peptides and consequently addresses 
a previous research gap. Our cost-effectiveness model lever-
ages risk equations to allow representative disease progres-
sion modeling for a multifactorial condition such as HFrEF.
Over a 30-year lifetime horizon, vericiguat plus PSoCT 
was associated with gains in life expectancy and QALYs 
and an incremental cost of $82,488 per QALY gained com-
pared with PSoCT alone in the VICTORIA ITT population 
in the base case. Sensitivity analyses showed that the base-
case analysis results were robust and suggest that vericiguat 
on top of PSoCT is cost effective at a WTP threshold of 
$100,000 in the US. It will be important to understand the 
real-world effectiveness of vericiguat in the upcoming years 
and to update our cost-effectiveness analysis with recent 
real-world data once they become available.
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